SG11201804641WA - Methods for generating functional hematopoietic stem cells - Google Patents

Methods for generating functional hematopoietic stem cells

Info

Publication number
SG11201804641WA
SG11201804641WA SG11201804641WA SG11201804641WA SG11201804641WA SG 11201804641W A SG11201804641W A SG 11201804641WA SG 11201804641W A SG11201804641W A SG 11201804641WA SG 11201804641W A SG11201804641W A SG 11201804641WA SG 11201804641W A SG11201804641W A SG 11201804641WA
Authority
SG
Singapore
Prior art keywords
methods
international
cells
hscs
hematopoietic stem
Prior art date
Application number
SG11201804641WA
Inventor
Dhvanit I Shah
George Q Daley
Original Assignee
Brigham & Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital Inc filed Critical Brigham & Womens Hospital Inc
Publication of SG11201804641WA publication Critical patent/SG11201804641WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0271—Chimeric animals, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/12—Animals modified by administration of exogenous cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/28—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from vascular endothelial cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/52—Fibronectin; Laminin

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -' Organization International Bureau .... ...Yeid (43) International Publication Date .... ..sr ,„„..) 8 June 2017 (08.06.2017) W I P0 1 PCT (10) WO International 111111111111311111111111111111111111111111111111111111111111111111111311111111111111111 2017/096215 Publication Al Number (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A01N 63/00 (2006.01) C12N 5/02 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, C12N 5/071 (2010.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (21) International Application Number: KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, PCT/US2016/064706 MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (22) International Filing Date: OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 2 December 2016 (02.12.2016) SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (25) Filing Language: English ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 62/262,464 3 December 2015 (03.12.2015) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 62/332,853 6 May 2016 (06.05.2016) US TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (71) Applicant . THE BRIGHAM AND WOMEN'S HOS- DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, PITAL, INC. [US/US]; 75 Francis Street, Boston, MA LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, 02115 (US). SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, (72) Inventors: SHAH, Dhvanit I.; 1036 Main Street, Apt. 5, GW, KM, ML, MR, NE, SN, TD, TG). Malden, Massachusetts 02148 (US). DALEY, George Q.; Published: 50 Young Road, Weston, Massachusetts 02193 (US). — with international search report (Art 21(3)) (74) Agents: DEYOUNG, Janice Kugler et al.; Fish & before the expiration of the time limit for amending the Richardson P.C., P.O. Box 1022, Minneapolis, Minnesota claims and to be republished in the event of receipt of 55440-1022 (US). amendments (Rule 48.2(h)) (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (54) Title: METHODS FOR GENERATING FUNCTIONAL HEMATOPOIETIC STEM CELLS Il .4t * * /0 / 1 , • 4- , • • , - .; . - S ,,„ „ rt 1 Sei % ) w., CAM R n GSkir 4 -Pr m G5K2'35 GSK r in KTE720 Il N FIG. 9B Ct\ 0 ----. (57) : Methods for preparing populations of hematopoietic stem cells (HSCs), e.g., autologous and/or allogenic HSCs, us - I I: ing mechanical stretching or transient receptor potential cation channel-subfamily vanilloid member 4 (Trpv4) agonists, and methods c:::, of use of the HSCs in transplantation are provided. Specifically, the methods comprising providing a population cells comprising el hemogenic endothelial (HE) cells, contacting the HE cells with an amount of an agonist of Trpv4; and/or subjecting the cells to cyc - 0 lic 2-dimensional stretching, for a time and under conditions sufficient to stimulating endothelial-to-HSC transition. Further dis- closed are methods of treating malignant or non-malignant hematologic, metabolic, or immune disorders comprising administering to a subject a therapeutically effective amount of HSCs obtained by the methods.
SG11201804641WA 2015-12-03 2016-12-02 Methods for generating functional hematopoietic stem cells SG11201804641WA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562262464P 2015-12-03 2015-12-03
US201662332853P 2016-05-06 2016-05-06
PCT/US2016/064706 WO2017096215A1 (en) 2015-12-03 2016-12-02 Methods for generating functional hematopoietic stem cells

Publications (1)

Publication Number Publication Date
SG11201804641WA true SG11201804641WA (en) 2018-06-28

Family

ID=58797932

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201804641WA SG11201804641WA (en) 2015-12-03 2016-12-02 Methods for generating functional hematopoietic stem cells

Country Status (10)

Country Link
US (2) US11162073B2 (en)
EP (1) EP3383182B1 (en)
JP (1) JP6995750B2 (en)
KR (1) KR20180081821A (en)
CN (1) CN108601356B (en)
AU (2) AU2016362508B2 (en)
CA (1) CA3007299A1 (en)
ES (1) ES2951488T3 (en)
SG (1) SG11201804641WA (en)
WO (1) WO2017096215A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107306853B (en) * 2016-04-25 2020-10-13 南方医科大学 Myelodysplastic syndrome animal model and application of transgenic zebra fish in preparation of animal model
US20200263136A1 (en) * 2017-11-08 2020-08-20 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Methods of preparing hematopoietic progenitor cells in vitro
KR20210018437A (en) 2018-06-07 2021-02-17 더 브리검 앤드 우먼즈 하스피털, 인크. Method for producing hematopoietic stem cells
CA3164120A1 (en) * 2019-12-09 2021-06-17 The Brigham And Women's Hospital, Inc. Methods for generating hematopoietic stem cells
CN117597435A (en) * 2021-03-31 2024-02-23 迦鲁达细胞疗法公司 Pluripotent stem cell derived hematopoietic lineages
WO2024020587A2 (en) 2022-07-22 2024-01-25 Tome Biosciences, Inc. Pleiopluripotent stem cell programmable gene insertion
WO2024077153A1 (en) * 2022-10-05 2024-04-11 Garuda Therapeutics, Inc Pluripotent stem cell-derived megakaryocytes and platelets
CN115975925B (en) * 2023-03-21 2023-09-08 天九再生医学(天津)科技有限公司 Method for inducing human pluripotent stem cells to differentiate into natural killer cells by variable-speed suspension

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006105475A1 (en) 2005-03-31 2006-10-05 Smithkline Beecham Corporation Novel compounds
WO2007102812A2 (en) 2006-03-07 2007-09-13 Regenetech, Inc. Natively glycosylated mammalian biological molecules produced by eletromagnetically stimulating living mammalian cells
JP2009507855A (en) 2005-09-08 2009-02-26 スミスクライン・ビーチャム・コーポレイション Acyclic 1,4-diamine and use thereof
EP1968590A2 (en) 2005-12-15 2008-09-17 SmithKline Beecham Corporation Novel compounds
EP1981596A4 (en) 2006-01-11 2010-09-01 Glaxosmithkline Llc Novel compounds
WO2007098393A2 (en) 2006-02-17 2007-08-30 Smithkline Beecham Corporation Compounds and methods for treating diseases with trpv4 channel receptors
JP5794510B2 (en) 2010-08-31 2015-10-14 国立大学法人 千葉大学 Efficient induction and amplification method of hematopoietic stem cells
WO2013086029A1 (en) 2011-12-05 2013-06-13 Primorigen Biosciences Inc. Compositions and methods for differentiating pluripotent stem cells into primitive blood cells and uses thereof
WO2013116307A1 (en) 2012-01-30 2013-08-08 Mount Sinai School Of Medicine Method for programming differentiated cells into hematopoietic stem cells
WO2014018230A2 (en) 2012-07-25 2014-01-30 Albert Einstein College Of Medicine Of Yeshiva University Methods to isolate human mesenchymal stem cells
CN105051184B (en) 2013-01-15 2018-08-10 康奈尔大学 It is hematopoiesis multi-lineage progenitor cells to be reprogrammed human endothelial cells by the given factor

Also Published As

Publication number Publication date
EP3383182A1 (en) 2018-10-10
US20190177695A1 (en) 2019-06-13
CA3007299A1 (en) 2017-06-08
EP3383182A4 (en) 2019-07-31
JP2018535683A (en) 2018-12-06
WO2017096215A1 (en) 2017-06-08
AU2021240191B2 (en) 2024-01-04
ES2951488T3 (en) 2023-10-23
AU2021240191A1 (en) 2021-11-04
JP6995750B2 (en) 2022-02-04
CN108601356A (en) 2018-09-28
US11162073B2 (en) 2021-11-02
EP3383182B1 (en) 2023-06-07
KR20180081821A (en) 2018-07-17
EP3383182C0 (en) 2023-06-07
AU2016362508A1 (en) 2018-06-21
US20220049221A1 (en) 2022-02-17
CN108601356B (en) 2023-01-10
AU2016362508B2 (en) 2021-07-01

Similar Documents

Publication Publication Date Title
SG11201804641WA (en) Methods for generating functional hematopoietic stem cells
SG11201903331QA (en) Restimulation of cryopreserved tumor infiltrating lymphocytes
SG11201909949XA (en) Targeted immunotolerance
SG11201804132UA (en) Eif4-a-inhibiting compounds and methods related thereto
SG11201900344YA (en) Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
SG11201804814YA (en) Materials and methods for delivering nucleic acids to cochlear and vestibular cells
SG11201810162PA (en) Polynucleotides encoding citrin for the treatment of citrullinemia type 2
SG11201804901WA (en) Compounds for the treatment of cancer and inflammatory disease
SG11201808990QA (en) Compositions for topical application of compounds
SG11201805570WA (en) Systems and methods for long term transdermal administration
SG11201805162VA (en) Plasmid constructs for heterologous protein expression and methods of use
SG11201407819UA (en) Improved methods of cell culture for adoptive cell therapy
SG11201805072PA (en) Nicotine powder delivery system
SG11201809499UA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201807041PA (en) Improved preparations of adult liver progenitor cells
SG11201808762XA (en) Diagnostic methods for patient specific therapeutic decision making in cancer care
SG11201807051VA (en) Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201805052YA (en) Therapeutic methods using erythrocytes
SG11201805204WA (en) Nicotine particle capsule
SG11201807255YA (en) Treatment of autoimmune diseases with combinations of rxr agonists and thyroid hormones
SG11201805771XA (en) Systems and methods for preparation of platelets
SG11201807915QA (en) Differentiation of pluripotent stem cells to intestinal midgut endoderm cells
SG11201804220SA (en) Activated stem cells and systemic treatment methods for infected wounds
SG11201806545WA (en) Compositions comprising fatty acids and their use